

histologically validated to provide information on the microstructure of the myocardium.<sup>1–3</sup> There is a standard helical myocyte arrangement in the situs solitus (SS) heart, as viewed from the apex; left-handed in the epicardium, circumferential in the mesocardium and right-handed in the endocardium. This generates the opposing basal clockwise rotation and apical anticlockwise rotation necessary for torsion.<sup>4</sup>

However in situs inversus totalis (SIT) there is mirror image arrangement of the visceral organs. There are no histological studies assessing how myocardial microstructure is affected in SIT. DT-CMR offers a unique opportunity to evaluate the microstructural abnormalities in SIT.

**Methods** 12 SIT patients and 12 matched healthy volunteers were scanned in a 3T Siemens Skyra scanner. DT-CMR was performed at peak systole in the short axis at base, mid and apex. 2 people had whole heart tractography. A STEAM sequence with  $b_{\text{main}}=600 \text{ s/mm}^2$  and  $b_{\text{ref}}=150 \text{ s/mm}^2$  was used, as previously described.<sup>3</sup> Strain and torsion assessment was performed using DENSE5.

**Results** Patients were age and sex-matched (SIT 39.5 and SS 34.5 years, 3/12 male). Myocyte organisation at base, mid and apex was significantly different in SIT hearts compared to the SS hearts. Figure 1 shows example tractography. In SS, the endocardial positive helix angle (HA) progressed to a negative HA in the epicardium. In SIT hearts this pattern was inverted at the base and approached normal at the apex, with a mid-ventricular transition zone.

Mid-ventricular peak radial and circumferential strain were reduced in SIT ( $0.4 \pm 0.16$  vs  $0.56 \pm 0.16$ ,  $p=0.02$ , and  $-0.16 \pm 0.02$  vs  $-0.18 \pm 0.01$ ,  $p=0.04$  respectively). Peak absolute torsion was reduced in SIT  $3.6^\circ$  [ $3.6^\circ$ ] vs  $8.0^\circ$  [ $3.5^\circ$ ].

**Conclusion** This is the first human DT-CMR study of SIT hearts. We demonstrate that the SIT heart has an inverted myocyte orientation at the base that approaches normal towards the apex. Peak absolute torsion is reduced. Peak radial and circumferential strain are also reduced at the mid-ventricle. The deranged microstructure in SIT has functional effects, the long-term outcomes of which require further study.

## REFERENCES

1. Reese TG, Weisskoff RM, Smith RN, et al. Imaging myocardial fibre architecture *in vivo* with magnetic resonance. *Magn Reson Med* 1995;**34**(6):786–791.
2. Scollan DF, Holmes A, Winslow R, et al. Histological validation of myocardial microstructure obtained from diffusion tensor magnetic resonance imaging. *Am J Physiol Heart Circ Physiol* 1998;**275**(6):H2308–H2318.
3. NIELLES-VALLESPIN S, KHALIQUE Z, FERREIRA PF, et al. Assessment of Myocardial Microstructural Dynamics by *In Vivo* Diffusion Tensor Cardiac Magnetic Resonance. *J Am Coll Cardiol* 2017;**69**(6):661–676.
4. Sengupta PP, AJ Tajik, K Chandrasekaran, et al. Twist Mechanics of the Left Ventricle: Principles and Application. *JACC: Cardiovascular Imaging* 2008;**1**(3):366–376.
5. Scott AD, Tayal U, NIELLES-VALLESPIN S, et al. Accelerating cine DENSE using a zonal excitation. *J Cardiovasc Magn Reson* 2016;**18**(1):050.

019


## CHEMOTHERAPY-INDUCED CARDIOTOXICITY: COULD A TRANSLATIONAL CARDIAC MRI MODEL HELP IDENTIFY PATIENTS AT RISK?

<sup>1,2</sup>L Cove-Smith\*, <sup>3</sup>M Schmitt, <sup>1</sup>C Dive, <sup>1</sup>A Backen, <sup>2</sup>N Mescallado, <sup>4</sup>R Roberts, <sup>4</sup>H Mellor, <sup>5</sup>D Morris, <sup>5</sup>J Naish, <sup>5</sup>A Jackson, <sup>4</sup>J Kirk, <sup>4</sup>A Hargreaves, <sup>4</sup>M Galvin, <sup>4</sup>S Smith, <sup>4</sup>S Brocklehurst, <sup>4</sup>S Price, <sup>4</sup>C Betts, <sup>4</sup>P Hockings, <sup>4</sup>N Woodhouse, <sup>2,6</sup>J Radford, <sup>2,6</sup>K Linton. <sup>1</sup>Clinical and Experimental Pharmacology, The Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK; <sup>2</sup>Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; <sup>3</sup>Cardiology, University Hospital of South Manchester, Manchester, UK; <sup>4</sup>Astrazeneca, Macclesfield, UK; <sup>5</sup>Biomedical Imaging Institute, University of Manchester, Manchester, UK; <sup>6</sup>Institute of Cancer Sciences, University of Manchester, Manchester, UK

10.1136/heartjnl-2017-311399.19

**Background** Cancer survivorship is an international priority and mortality from cardiac damage is one of the greatest concerns. Anthracycline chemotherapy is cardiotoxic but remains highly effective against cancer.

**Methods** This translational project involved the development of a pre-clinical rat model of progressive anthracycline-induced cardiotoxicity (1.25mg/m<sup>2</sup> doxorubicin weekly for 8 doses) and a concurrent clinical study of 30 cancer patients receiving 6 cycles of curative anthracycline therapy (doxorubicin 50mg/m<sup>2</sup>). A bespoke cardiac magnetic resonance imaging (CMR) protocol was developed which included longitudinal T1



Abstract 18 Figure 1 Tractography of a SIT and SS heart.

mapping (modified look-locker) to estimate extracellular volume (ECV), T2 mapping (to quantify oedema) and strain analysis. A panel of circulating biomarkers (including inflammatory, ischaemic and fibrosis markers) was evaluated by multiplex ELISA. Longitudinal histological analysis was performed in the rats and correlated with imaging and biomarker findings.

**Results** Left ventricular function (LVEF) declined steadily during treatment in rats and humans. Persistent LV dysfunction was seen in 23% of patients 12 months after therapy. Peak Troponin I levels correlated with fall in (LVEF) and circulating levels translated well between rat and humans. However, levels did not peak until the final cycle of chemotherapy when significant LV decline had already occurred. There was no significant change in the other circulating biomarkers. ECV did not change significantly during treatment but lower baseline ECV correlated with a greater fall in LVEF. Microscopic changes were seen in the rat myocardium after 6 doses of doxorubicin but electron-microscopy revealed mitochondrial damage after just one dose.

**Conclusions** This translational approach enabled forward and back translation leading to the development of a clinically relevant pre-clinical cardiotoxicity model. Troponin I was the most informative circulating biomarker but peaked at the end of therapy too late to modify treatment and prevent LV decline. The model has the potential to be used to identify earlier biomarkers and evaluate cardioprotective strategies. The imaging findings showed that fibrosis cannot be detected on CMR within one year of chemotherapy but generated a new hypothesis that patients with 'healthier hearts' may be a greatest risk of drug-induced cardiotoxicity.

#### 020 COMPREHENSIVE CARDIOVASCULAR MAGNETIC RESONANCE ASSESSMENT OF ANDERSON-FABRY CARDIOMYOPATHY- NATURAL HISTORY AND ASSESSMENT OF TREATMENT EFFECT

Anna Reid, Chris Miller, Ana Jovanovic, Peter Woolfson, Nik Abidin, David Clark, Wendy Gamlin, Glyn Coutts, Matthias Schmitt.

10.1136/heartjnl-2017-311399.20

**Background** The Anderson Fabry Cardiomyopathy (AFC) is heterogeneous, complex, and its pathophysiology remains incompletely understood. There is uncertainty regarding the optimal timing and impact of enzyme replacement therapy (ERT) in cardiac involvement, with a pressing need for biomarkers able to identify early disease, monitor and guide treatment.

**Objectives** The aims of this study were two-fold: 1) to perform comprehensive cardiac phenotyping in a large cohort of Anderson-Fabry disease (AFD), and 2) characterise their short-term natural history and assess the impact of ERT using multiparametric Cardiac Magnetic resonance imaging (MPCMRi), echocardiography and ECG analysis.

**Methods** 113 prospectively enrolled, genetically-confirmed, AFD patients were compared to 20 age-matched healthy volunteers (HVs). 37 of these patients re-attended for a one-year follow-up scan, and were sub-grouped according to treatment status (newly started on ERT, ERT naïve, and established on ERT).

**Results** The AFC is characterised by increased LV mass of several different hypertrophic patterns, impaired LV global

longitudinal strain and left atrial function, low myocardial native T1, high T2, and increased extracellular volume fraction. Significantly higher T1s were seen in the inferolateral wall, even before the development of increased wall thickness or LV mass, or LGE. A newly proposed marker of disease severity, the 'T1 ratio', reflects the relationship between inferolateral and remote myocardial T1, and strongly correlated with LV mass, percentage LGE and ECV fraction, whilst avoiding potential uncertainty caused by pseudo-normalisation of T1s in severe AFD.

ERT initiation reduced LVM. T1 values (excluding the inferolateral wall) fell significantly in untreated patients ( $974 \pm 36$  ms v  $955 \pm 44$  ms,  $p=0.04$ ) associated with a significant increase in voxel based spread ( $288$  v  $350$ ,  $p=0.02$ ), whereas both treatment groups showed no change in T1 values. The T1 ratio showed a trend towards improvement ( $0.94 \pm 0.08$  v  $0.98 \pm 0.1$ ,  $p=0.05$ ) in the established ERT group. Electrocardiography and echocardiography did not detect disease progression or treatment effects in any group.

**Conclusions** AFC is a complex pathology with intracellular and extracellular disease components. MPCMRi elucidates these disease processes and allows early disease detection, and possibly disease and treatment monitoring.

#### 021 PERFUSION CARDIOVASCULAR MAGNETIC RESONANCE (CMR) – CAN DAVID (RESOLUTION) TAKE ON GOLIATH (COVERAGE) AGAIN?

<sup>1</sup>Joy S Shome, <sup>2</sup>Kerem C Tezcan, <sup>1</sup>Sohaib Nazir, <sup>1</sup>Markus Henningsson, <sup>1</sup>Adriana Villa, <sup>1</sup>Imran Rashid, <sup>1</sup>David Snell, <sup>4</sup>Antonios Pavlidis, <sup>4</sup>Brian Clapp, <sup>3,4</sup>Simon Redwood, <sup>5</sup>Kamran Baig, <sup>1</sup>Reza Razavi, <sup>1,4</sup>Tevfik F Ismail, <sup>1</sup>Amedeo Chiribiri, <sup>3,4</sup>Divaka Perera, <sup>2</sup>Sebastian Kozerke, <sup>1,6</sup>Sven Plein. <sup>1</sup>Division of Imaging Sciences, The Rayne Institute, King's College London, St. Thomas' Hospital, London, UK; <sup>2</sup>Department of Biomedical Engineering, ETH Zurich, Zurich, Switzerland; <sup>3</sup>Cardiovascular Division, The Rayne Institute, King's College London, St. Thomas' Hospital, London, UK; <sup>4</sup>Department of Cardiology, St. Thomas' Hospital, London, UK; <sup>5</sup>Department of Cardiothoracic Surgery, St. Thomas' Hospital, London, UK; <sup>6</sup>Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK

10.1136/heartjnl-2017-311399.21

**Background** Both 3D and high-resolution 2D-perfusion CMR accurately detect coronary artery disease (CAD). 3D provides whole-heart coverage whereas 2D better detects sub-endocardial ischaemia. We compared the diagnostic accuracy of both techniques to detect flow limiting CAD as measured by fractional flow reserve (FFR). We also investigated the relative accuracy of these tools in identifying prognostically significant myocardial ischaemic burden (MIB).

**Methods** Patients with suspected angina underwent high spatial resolution 2D *k-t* SENSE (3 slices, in-plane spatial resolution  $1.3 \times 1.3 \times 8$  mm) and 3D *k-t* PCA whole heart (12 slices, in plane spatial resolution  $2.3 \times 2.3 \times 5$  mm) myocardial perfusion CMR during adenosine stress in a single sitting. Invasive coronary angiography with FFR (for stenoses of 50-80% severity visually) was performed in all patients prior to revascularisation. Perfusion defects were contoured using circleCVI software and MIB was calculated for both 2D and 3D-CMR. The anatomical and functional BCIS-1 Jeopardy Scores (BCIS-JS) scores were calculated from the invasive angiograms. **Results** Forty-seven patients were included in the analysis. Per-patient sensitivity, specificity, diagnostic accuracy, PPV, and NPV in identifying flow-limiting CAD were 76%, 100%, 85%, 100%, 72% for 2D